PL3 Stock Chart & Stats
€1.79
€0.00(0.00%)
At close: 4:00 PM EST
€1.79
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.35 - €2.64
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€109.77M
Enterprise Value€152.96M
Total Cash (Recent Filing)€995.98K
Total Debt (Recent Filing)€407.02K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 13, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding63,726,616
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.02Price Target Upside347.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline AdvancementFDA clearance allows TuHURA to advance TBS-2025 into a Phase 1b study for patients with relapsed or refractory mutNPM1 AML, an area described as having unmet medical need. This expands clinical validation opportunities and could support later development if responses are encouraging.
Low Current LeverageThe company currently has low leverage and positive equity, giving it a more manageable capital structure than the operating losses alone would suggest. Limited debt burden may preserve flexibility to direct available capital toward clinical development, although funding needs remain substantial.
Access To Long-term LiquidityThe revolving facility provides multi-year access to debt capital and gives TuHURA an established source of liquidity for general corporate purposes. This can help sustain research and clinical programs between financing events and provides greater operational flexibility during development.
Bears Say
No Commercial RevenueZero reported revenue confirms that TuHURA remains pre-commercial and has not yet demonstrated product-market commercialization or internally generated sales. Until a candidate reaches approval and launch, the business must fund development without an operating revenue base to absorb its expenses.
Widening Net LossesLosses have expanded materially over the periods provided, indicating that operating expenses are rising faster than any offsetting income because the company is still developing its pipeline. Continued losses can increase the capital required to reach meaningful clinical and commercial milestones.
Persistent Cash Burn And Funding DependenceDeeply negative operating and free cash flow shows that TuHURA consumes substantial cash to maintain operations and advance development. The magnitude and worsening trend make continued external financing important, which can constrain strategy and increase exposure to future capital-raising needs.
TuHURA Biosciences News
PL3 FAQ
What was TuHURA Biosciences’s price range in the past 12 months?
TuHURA Biosciences lowest stock price was €0.35 and its highest was €2.64 in the past 12 months.
What is TuHURA Biosciences’s market cap?
TuHURA Biosciences’s market cap is €109.77M.
When is TuHURA Biosciences’s upcoming earnings report date?
TuHURA Biosciences’s upcoming earnings report date is Nov 13, 2026 which is in 34 days.
How were TuHURA Biosciences’s earnings last quarter?
TuHURA Biosciences released its earnings results on Aug 14, 2026. The company reported -€0.12 earnings per share for the quarter, beating the consensus estimate of -€0.132 by €0.011.
Is TuHURA Biosciences overvalued?
According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued.
Does TuHURA Biosciences pay dividends?
TuHURA Biosciences does not currently pay dividends.
What is TuHURA Biosciences’s EPS estimate?
TuHURA Biosciences’s EPS estimate is -0.12.
How many shares outstanding does TuHURA Biosciences have?
TuHURA Biosciences has 63,726,616 shares outstanding.
What happened to TuHURA Biosciences’s price movement after its last earnings report?
TuHURA Biosciences reported an EPS of -€0.12 in its last earnings report, beating expectations of -€0.132. Following the earnings report the stock price went down -1.508%.
Which hedge fund is a major shareholder of TuHURA Biosciences?
Currently, no hedge funds are holding shares in DE:PL3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TuHURA Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.02 (347.84% Upside)
€8.02 (347.84% Upside)
Blogger Sentiment
Bullish
DE:PL3 Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.05%
12-Months-Change
Fundamentals
Return on Equity
-154.32%
Trailing 12-Months
Asset Growth
-8.30%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TuHURA Biosciences
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
PL3 Stock 12 Month Forecast
Average Price Target
€8.02
▲(347.84% Upside)
Technical Analysis
Agenus
―
Inovio Pharmaceuticals
―
Skye Bioscience
―
Biomea Fusion
―
Cognition Therapeutics
―